▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Apr 25, 2014 by Todd Campbell

Can Biogen Dethrone Baxter in Hemophilia?

Biogen (BIIB) is launching its first drugs for the treatment of hemophilia this year, challenging Baxter's (BAX) long-held dominance.

Apr 25, 2014 by Todd Campbell

Is There Value In Cytokinetics Following Its 60% Drop?

Cytokinetics (CYTK) mid stage trial for its promising ALS drug failed, shifting attention to collaborations with Amgen (AMGN) and Astellas (ALPMY).

Apr 24, 2014 by Todd Campbell

What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio

Johnson & Johnson's (JNJ) Olysio and Gilead's (GILD) Sovaldi posted blockbuster run rates in the first quarter, but sales could soon be challenged by AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK).

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Aetna, Inc. Continues the Medicaid Winning Steak

Aetna (AET) joined United Healthcare (UNH) and Centene (CNC) in reporting robust first quarter sales and profit growth tied to rising Medicaid enrollment.

Apr 24, 2014 by Todd Campbell

3 Drugs Johnson & Johnson’s Investors Better Know About

Johnson & Johnson's (JNJ) sales are being driven by a handful of fast-growing drugs. Here are three investors should be watching because of competitive threats from AstraZeneca (AZN), Pfizer (PFE), and Medivation (MDVN).

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Does Medidata's Stumble Present An Opportunity?

Medidata's (MDSO) first quarter results left investors unimpressed, but a growing industry suggests that Medidata and competitors Oracle (ORCL) Health and IMS (IMS) still have room to expand.

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Biogen's Tecfidera Wins More Share

Biogen's (BIIB) dominance in multiple sclerosis drove sales 50% higher in the first quarter, as Tecfidera successfully expanded market share.

Apr 23, 2014 by Todd Campbell

Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter

Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing Johnson & Johnson's (JNJ) Olysio.

Apr 22, 2014 by Todd Campbell

Earnings Roundup: athenahealth's Disappointing Quarter

The market for healthcare IT has never been stronger, but that did little to calm athenahealth's (ATHN) investors' worry over uninspiring earnings.

Apr 22, 2014 by Todd Campbell

Earnings Roundup: Centene's Medicaid Miracle

Centene (CNC) joined United Healthcare (UNH) in reporting impressive Medicaid revenue, setting the stage for Molina (MOH) to beat when it reports on May 1st.

Apr 22, 2014 by Todd Campbell

Earnings Roundup: Baxter International Grows Ahead of Its Spin-Off

Sales at Baxter (BAX) biopharma and medical device businesses headed higher in the first quarter, suggesting a bright future for Baxter's planned separation of its biopharma and medical device business next year.

Apr 22, 2014 by Todd Campbell

Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Here's what you need to know about Valeant's (VRX) planned $45 billion acquisition of Allergan (AGN),

Apr 21, 2014 by Todd Campbell

Warfarin's Loss is Johnson & Johnson's Gain

Factor Xa-inhibiting anticoagulants like Johnson & Johnson's Xarelto are rapidly winning prescriptions away from warfarin and Boehringer's Pradaxa.

Apr 21, 2014 by Todd Campbell

Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?

Johnson's Invokana is about to face a host of new SGLT2 competitors from AstraZeneca, Merck, and Eli Lilly.

Apr 20, 2014 by Todd Campbell

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps

A recall in Abbott Labs (ABT) nutrition segment gave Mead Johnson (MJN) an edge, but that and other short-term hurdles shouldn't distract investors from the company's long-term opportunity.

Apr 18, 2014 by Todd Campbell

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.

Apr 17, 2014 by Todd Campbell

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Slow growth from medical device and consumer goods masked robust sales in Johnson & Johnson's drug business.

Apr 17, 2014 by Todd Campbell

Earnings Roundup: Did Obamacare Swamp United Healthcare's Quarter?

Medicaid membership surged at United Healthcare (UNH) in Q1, offsetting headwinds tied to Obamacare fees and higher taxes, and suggesting strong results for Medicaid insurers Molina (MOH) and Centene (CNC).

Apr 17, 2014 by Todd Campbell

3 Reasons Rite Aid Continues to Crush the Market

Shares in Rite Aid (RAD) may keep heading higher thanks to these three reasons.

Apr 17, 2014 by Todd Campbell

Earnings Roundup: St. Jude's 1 Bright Spot

St Jude's (STJ) electrophysiology business is the one bright spot in an otherwise dim earnings report.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services